메뉴 건너뛰기




Volumn 124, Issue 2, 2011, Pages 172-176

Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in newly diagnosed type 2 diabetics

Author keywords

Diabetes; Early phase insulin secretion; Gliclazide; Repaglinide; Type 2

Indexed keywords

CHOLESTEROL; GLICLAZIDE; GLUCOSE; INSULIN; REPAGLINIDE; TRIACYLGLYCEROL;

EID: 79551718932     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.02.003     Document Type: Article
Times cited : (10)

References (19)
  • 1
    • 0028817815 scopus 로고
    • U.K. prospective diabetes study 16: Overview of 6 years' therapy of type II diabetes: A progressive disease
    • U.K. Prospective Diabetes Study Group
    • U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258.
    • (1995) Diabetes , vol.44 , pp. 1249-1258
  • 2
    • 0032742992 scopus 로고    scopus 로고
    • The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus
    • Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-794.
    • (1999) J Clin Invest , vol.104 , pp. 787-794
    • Weyer, C.1    Bogardus, C.2    Mott, D.M.3    Pratley, R.E.4
  • 3
    • 64249171985 scopus 로고    scopus 로고
    • Management of Chinese patients with type 2 diabetes, 1998-2006: The Diabcare-China surveys
    • Pan C, Yang W, Jia W, Weng J, Tian H. Management of Chinese patients with type 2 diabetes, 1998-2006: the Diabcare-China surveys. Curr Med Res Opin 2009; 25: 39-45.
    • (2009) Curr Med Res Opin , vol.25 , pp. 39-45
    • Pan, C.1    Yang, W.2    Jia, W.3    Weng, J.4    Tian, H.5
  • 4
    • 0038077538 scopus 로고    scopus 로고
    • Loss of early insulin secretion leads to postprandial hyperglycaemia
    • Del Prato S. Loss of early insulin secretion leads to postprandial hyperglycaemia. Diabetologia 2003; 46(Suppl 1): M2-M8.
    • (2003) Diabetologia , vol.46 , Issue.SUPPL. 1
    • del Prato, S.1
  • 5
    • 34347379097 scopus 로고    scopus 로고
    • Improvement of insulin sensitivity and β-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial
    • Li J, Tian H, Li Q, Wang N, Wu T, Liu Y, et al. Improvement of insulin sensitivity and β-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial. Diabetes Obes Metab 2007; 9: 558-565.
    • (2007) Diabetes Obes Metab , vol.9 , pp. 558-565
    • Li, J.1    Tian, H.2    Li, Q.3    Wang, N.4    Wu, T.5    Liu, Y.6
  • 6
    • 3943054698 scopus 로고    scopus 로고
    • Restoration of early insulin secretion after a meal in type 2 diabetes: Effects on lipid and glucose metabolism
    • Dimitriadis G, Boutati E, Lambadiari V, Mitrou P, Maratou E, Brunel P, et al. Restoration of early insulin secretion after a meal in type 2 diabetes: effects on lipid and glucose metabolism. Eur J Clin Invest 2004; 34: 490-497.
    • (2004) Eur J Clin Invest , vol.34 , pp. 490-497
    • Dimitriadis, G.1    Boutati, E.2    Lambadiari, V.3    Mitrou, P.4    Maratou, E.5    Brunel, P.6
  • 7
    • 0031892659 scopus 로고    scopus 로고
    • Stimulation of insulin release by repaglinde and glibenclamide involves both common and distinct processes
    • Fuhlendorff J, Rorsman P, Kofod H, Brand CL, Rolin B, MacKay P, et al. Stimulation of insulin release by repaglinde and glibenclamide involves both common and distinct processes. Diabetes 1998; 47: 345-351.
    • (1998) Diabetes , vol.47 , pp. 345-351
    • Fuhlendorff, J.1    Rorsman, P.2    Kofod, H.3    Brand, C.L.4    Rolin, B.5    MacKay, P.6
  • 8
    • 0141672120 scopus 로고    scopus 로고
    • Early-phase prandial insulin secretion: Its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide
    • Owens DR, Cozma LS, Luzio SD. Early-phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide. Diabetes Nutr Metab 2002; 15(6 Suppl): 19-27.
    • (2002) Diabetes Nutr Metab , vol.15 , Issue.6 SUPPL. , pp. 19-27
    • Owens, D.R.1    Cozma, L.S.2    Luzio, S.D.3
  • 9
    • 1842334456 scopus 로고    scopus 로고
    • Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
    • The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
    • The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20(Suppl 1): 1183-1197.
    • (1997) Diabetes Care , vol.20 , Issue.SUPPL. 1 , pp. 1183-1197
  • 10
    • 0038077476 scopus 로고    scopus 로고
    • The role of oral antidiabetic agents: Why and when to use an early-phase insulin secretion agent in Type II diabetes mellitus
    • Standl E, Füchtenbusch M. The role of oral antidiabetic agents: why and when to use an early-phase insulin secretion agent in Type II diabetes mellitus. Diabetologia 2003; 46(Suppl 1): M30-M36.
    • (2003) Diabetologia , vol.46 , Issue.SUPPL. 1
    • Standl, E.1    Füchtenbusch, M.2
  • 11
    • 28244447065 scopus 로고    scopus 로고
    • Assessment and comparison of the efficacy and safety profiles of repaglinide and gliclazide in Korean patients with Type 2 diabetes
    • A440:1834 PO
    • Seol Kim Y, Lee HC, Han IK, Yeo JP, Jorgensen LN. Assessment and comparison of the efficacy and safety profiles of repaglinide and gliclazide in Korean patients with Type 2 diabetes. Diabetes 2001; 50 (Suppl 2) A440:1834 PO.
    • (2001) Diabetes , vol.50 , Issue.SUPPL. 2
    • Seol, K.Y.1    Lee, H.C.2    Han, I.K.3    Yeo, J.P.4    Jorgensen, L.N.5
  • 12
    • 0033592101 scopus 로고    scopus 로고
    • Glucose tolerance and mortality: Comparison of WHO and American Diabetic Association diagnostic criteria
    • The DECODE Study Group
    • The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. Lancet 1999; 354: 617-621.
    • (1999) Lancet , vol.354 , pp. 617-621
  • 13
    • 1542708361 scopus 로고    scopus 로고
    • Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents
    • Furlong NJ, Hulme SA, O'Brien SV, Hardy KJ. Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents. Diabet Med 2003; 20: 935-941.
    • (2003) Diabet Med , vol.20 , pp. 935-941
    • Furlong, N.J.1    Hulme, S.A.2    O'Brien, S.V.3    Hardy, K.J.4
  • 14
    • 77649238654 scopus 로고    scopus 로고
    • Effects of short-term therapy with different insulin secretagogues on glucose metabolism, lipid parameters and oxidative stress in newly diagnosed Type 2 Diabetes Mellitus
    • Li Y, Xu L, Shen J, Ran J, Zhang Y, Wang M, et al. Effects of short-term therapy with different insulin secretagogues on glucose metabolism, lipid parameters and oxidative stress in newly diagnosed Type 2 Diabetes Mellitus. Diabetes Res Clin Pract 2010; 88: 42-47.
    • (2010) Diabetes Res Clin Pract , vol.88 , pp. 42-47
    • Li, Y.1    Xu, L.2    Shen, J.3    Ran, J.4    Zhang, Y.5    Wang, M.6
  • 15
    • 0024602810 scopus 로고
    • Sulphonylurea antidiabetic drugs. An update of their clinical pharmacology and rational therapeutic use
    • Melander A, Bitzén PO, Faber O, Groop L. Sulphonylurea antidiabetic drugs. An update of their clinical pharmacology and rational therapeutic use. Drugs 1989; 37: 58-72.
    • (1989) Drugs , vol.37 , pp. 58-72
    • Melander, A.1    Bitzén, P.O.2    Faber, O.3    Groop, L.4
  • 16
    • 0022319015 scopus 로고
    • Incidence of severe side effects during therapy with sulfonylureas and biguanides
    • Berger W. Incidence of severe side effects during therapy with sulfonylureas and biguanides. Horm Metab Res 1985; 15: 111-115.
    • (1985) Horm Metab Res , vol.15 , pp. 111-115
    • Berger, W.1
  • 17
    • 34447511196 scopus 로고    scopus 로고
    • Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women
    • Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298: 299-308.
    • (2007) JAMA , vol.298 , pp. 299-308
    • Nordestgaard, B.G.1    Benn, M.2    Schnohr, P.3    Tybjaerg-Hansen, A.4
  • 19
    • 0027326414 scopus 로고
    • Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM
    • Wolffenbuttel BH, Nijst L, Sels JP, Menheere PP, Müller PG, Kruseman AC. Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM. Eur J Clin Pharmacol 1993; 45: 113-116.
    • (1993) Eur J Clin Pharmacol , vol.45 , pp. 113-116
    • Wolffenbuttel, B.H.1    Nijst, L.2    Sels, J.P.3    Menheere, P.P.4    Müller, P.G.5    Kruseman, A.C.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.